HeartBeam to Host Second Quarter 2023 Results Conference Call on Thursday August 10, 2023 at 4:30 p.m. Eastern Time
27 July 2023 - 10:31PM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector
electrocardiogram (VECG) platform intended for patient use at home,
will hold a conference call on Thursday August 10, 2023 at 4:30
p.m. Eastern time to discuss its results for the second quarter
ended June 30, 2023, and will be reviewing recent announcements,
ongoing initiatives, and key 2023 milestones. A press release
detailing these results will be issued prior to the call.
HeartBeam CEO and Founder Branislav Vajdic, PhD, President
Robert Eno and CFO Richard Brounstein will host the conference
call, followed by a question-and-answer period. The conference call
will be accompanied by a presentation, which can be viewed during
the webcast or accessed via the investor relations section of the
Company’s website here.
To access the call, please use the following information:
Date:
Thursday August 10, 2023
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific
time)
Dial-in:
1-877-704-4453
International Dial-in:
1-201-389-0920
Conference Code:
13739569
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1622204&tp_key=86e9e2b301
A telephone replay will be available approximately two hours
after the call and will run through November 10, 2023, by dialing
1-844-512-2921 from the U.S., or 1-412-317-6671 from international
locations, and entering replay pin number: 13739569. The replay can
also be viewed through the webcast link above and the presentation
utilized during the call will be available in the company’s
investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform
intended for patient use at home. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to assess their cardiac symptoms quickly and easily, so
care can be expedited, if required. HeartBeam has two patented
products in development. HeartBeam AIMI™ is software for acute care
settings that provides a 3D comparison of baseline and symptomatic
12-lead ECG to more accurately identify a heart attack. HeartBeam
AIMIGo™ is the first and only credit card-sized 12-lead output ECG
device coupled with a smart phone app and cloud-based diagnostic
software system to facilitate remote evaluation of cardiac
symptoms. HeartBeam AIMI and HeartBeam AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230727885552/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:media@heartbeam.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Nov 2024 to Dec 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Dec 2023 to Dec 2024